Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

PHA Partners & Events

From Precision Biology to Precision Medicine in Pulmonary Hypertension Revolutionizing Healthcare through Revolutionary Science

May 18, 2018

Sheraton Hotel, Palo Alto, California 625 El Camino Real
Palo Alto, CA 94301
United States

Despite numerous recent advances in pulmonary arterial hypertension (PAH), additional research is warranted to better understand disease pathogenesis, identify and deconstruct novel sources of biological and clinical heterogeneity across patients, and pave a road to new treatment paradigms.

The exciting field of precision biology arms researchers with powerful tools to study PAH pathobiology, such as single cell transcriptomics, spatial proteomics, lineage tracing and the use of induced pluripotent stem cells to model disease in a dish. These cutting-edge methods have the potential to transform the way we understand disease pathogenesis, identify specific treatment targets, and develop precise and highly effective PAH therapies.

Precision medicine is a therapeutic strategy that takes into account individual variability in genes, environment, and lifestyle to identify clinical phenotypes that would specifically benefit from targeted therapies.  The importance of precision medicine to the future of US health care has been stressed by president Obama in his Precision Medicine Initiative, which aims to provide clinicians with a way to integrate seemingly disparate data (e.g. genetics, proteomics, epigenetics, metabolomics, medical record data, etc.) into a framework that improves individual clinical outcomes and health care quality. Given the rapid advancement of high-throughput ‘Omics’ platforms, availability of sophisticated machine learning algorithms, and emergence of collaborative PAH biorepositories and phenotyping efforts, the time is ripe to discuss how state-of-the-art technologies can facilitate the translation of scientific discoveries into clinical tools for improved diagnosis and treatment of PAH patients.

With the recent advances in biology such as single cell transcriptomics and spacial proteomics, lineage tracing and the use of induced pluripotent stem cells to model diseases in a dish, we are equipped with novel tools to better study disease pathogenesis. This exciting new field of precision biology will transform the way we will understand disease pathogenesis, identify novel treatment targets and develop precise and effective therapies.  Precision medicine is an approach to disease treatment that takes into account individual variability in genes, environment, and lifestyle to identify clinical phenotypes that would benefit from targeted and highly effective therapies.  The importance of precision medicine to the future of US  health care had been stressed buy President Obama in his Precision Medicine Initiative, which aims to provide healthcare providers with a way to integrate seemingly disparate data points (e.g. genetics, proteomics, epigenetics, metabolomics, medical record data, etc.) into a platform that can improve clinical outcomes and quality of health care.  Given the growing advances in our understanding of the pathobiology and management of pulmonary arterial hypertension (PAH), the time is ripe to discuss how state-of-the-art sequencing strategies tailored to capture single cell genotypes along with growing applications for the use of integrated 'Omics technologies and machine-based learning could help facilitate the translation of scientific discoveries into clinical tools (e.g. biomarkers, prediction algorithms, clinical trial design, drug discovery, etc.) that can help improve our capacity to properly diagnose and design the optimal treatment strategy of PAH patients.

More Information: http://med.stanford.edu/phsymposium.html

Contact Information: Lori Barth
Adminstrative Associate
lbarth@stanford.edu